ACET at a glance
Adicet Bio Inc (ACET, SEC CIK 1720580) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as August 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Adicet Bio Inc (ACET) reported revenue of $5.8 million (down 46.1% from FY2024) and a net loss of $116.8 million. Diluted EPS was -$16.95.
- As of September 30, 2026, 15 institutional investment managers tracked by SignalX reported holding Adicet Bio Inc (ACET) shares worth $12.0 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.8M
- −46.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 15 funds
- $12.0M · +0 vs prior quarter
- Latest 8-K
- Nov 13, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, no products approved for commercial sale, unchanged from prior-year quarter
- Net loss $18.9M vs $26.9M YoY, operating expenses $19.8M vs $28.0M
- R&D $15.6M, down 32% YoY, worst decline from lower headcount and no new patient enrollment
- Cash, equivalents and short-term investments $100.9M at September 30, 2026, operating cash use $59.2M
- Going-concern doubt within 12 months, additional funding required, ADI-212 enrollment anticipated Q1 2027
Risk Factors
- Newly added AI regulatory risk: EU AI Act provisions effective August 2, 2026, increasing compliance obligations for high-risk systems
- Most material operational update: FDA cleared ADI-212’s IND in August 2026, with Phase 1 enrollment expected in fourth-quarter 2026
- Regulatory risk: China’s 2024 Negative List may prohibit foreign-invested entities from developing gene or stem-cell therapies
- Near-term clinical risk: prula-cel Phase 1 studies face enrollment delays from competition for eligible patients and trial sites
- Financial risk: $100.9 million in cash, equivalents and short-term Treasury investments funds operations into second-half 2027
AI summary of the ACET 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Director Andrew Sinclair resigned November 13, 2026 from the Board, Audit Committee and NCG Committee
- Board size reduced from seven to six, with no reported disagreement driving Sinclair’s departure
Item 2.02: Results of Operations and Financial Condition
- Adicet Bio announced financial results for the quarter ended September 30, 2026
- Full financial figures and management commentary appear in Exhibit 99.1, the accompanying press release
Item EX-99.1: Item EX-99.1
- Phase 1 prula-cel data showed 50% complete renal response and 54% DORIS remission at 12 months, supporting pivotal lupus development
- No Grade >2 CRS, ICANS, IEC-HS, or GvHD, strengthening potential outpatient use but requiring confirmation in larger studies
Item 8.01: Other Events
- Preliminary Phase 1 data: 50% of evaluable lupus nephritis patients achieved complete renal response at 12 months
- 54% achieved DORIS remission, with all 12-month responses ongoing through 12 to 21 months except one
Item EX-99.1: Item EX-99.1
- Phase 1 data support prula-cel advancement toward pivotal lupus nephritis testing, with start-up activities planned for 4Q 2026
- At 12 months, 54% achieved DORIS remission and 50% of evaluable lupus nephritis patients achieved complete renal response
Item EX-99.2: Item EX-99.2
- Interim Phase 1 data showed 50% 12-month complete renal response and 54% DORIS remission among 22 efficacy-evaluable LN/SLE patients
- Treatment-free benefit: all patients discontinued immunosuppressants, while all but one tapered steroids to ≤5 mg prednisone equivalent
Item 7.01: Regulation FD Disclosure
- Positive safety and efficacy data announced for prula-cel in systemic lupus erythematosus, including patients with lupus nephritis
- Preliminary Phase 1 data webcast scheduled for September 28, 2026
AI summaries of ACET 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ACET
Don't miss the next ACET filing
- Alerts as it files. A push when ACET files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ACET, by share count.
- Ask anything. An AI agent that reads every ACET filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Klickstein Lloyd | A | Aug 5, 2026 | 18,300 | - |
| Peng Katie | A | Jun 21, 2026 | 4,200 | - |
| Sinclair Andrew | A | Jun 21, 2026 | 4,200 | - |
| Chodakewitz Jeffrey | A | Jun 21, 2026 | 4,200 | - |
| Grissinger Michael | A | Jun 21, 2026 | 4,200 | - |
| DUBIN STEVE | A | Jun 21, 2026 | 4,200 | - |
| Klickstein Lloyd | A | Jun 21, 2026 | 4,200 | - |
| Aftab Blake | A | Jun 19, 2026 | 55,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $10.7M | $5.8M |
| Operating Income | -$152.0M | -$127.6M | -$122.1M |
| Net Income | - | -$117.1M | -$116.8M |
| Op. Margin | - | -1191.1% | -2113.8% |
| Net Margin | - | -1093.2% | -2021.9% |
| Balance Sheet | |||
| Total Assets | $207.3M | $220.2M | $192.4M |
| Equity | - | $186.6M | $159.2M |
| ROE | - | -62.8% | -73.4% |
| Per Share | |||
| EPS | - | $-1.33 | $-16.95 |
| Cash Flow | |||
| Operating CF | -$93.7M | -$92.4M | -$95.2M |
| CapEx | $4.5M | $1.1M | $1.7M |
Source: XBRL data in Adicet Bio Inc (ACET)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ACET share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 15 | $12.0M |
| Q2 2026 | 15 | $18.9M |
| Q1 2026 | 13 | $13.2M |
| Q4 2025 | 14 | $11.0M |
- Franklin Resources+97.6K (+16%)
- Vanguard Capital Management LLC+23.0K (+7%)
- Morgan Stanley+8.5K (+373%)
- Dimensional Fund Advisors+6.5K (+21%)
- JPMorgan Chase & Co+5 (+3%)
- Citadel Advisors LLC−152.4K (-35%)
- Renaissance Technologies LLC−51.1K (-19%)
- Two Sigma Investments−23.9K (-25%)
- BlackRock−1.1K (-2%)
- Citigroup+4.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 57 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ACET filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| 4 | Aug 7, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | - | - |
| 8-K | May 13, 2026 | - | - | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | - | |
| 4 | Apr 29, 2026 | - | - | - |
| 8-K | Apr 28, 2026 | - | - | - |
| 4 | Apr 13, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Mar 27, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ACET SEC filings: frequently asked questions
Which institutions hold ACET stock?
As of September 30, 2026, the largest Adicet Bio Inc (ACET) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($2.6 million), Franklin Resources ($2.2 million), Citadel Advisors LLC ($2.0 million), Renaissance Technologies LLC ($1.5 million), Carlyle Group ($1.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ACET's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Adicet Bio Inc (ACET) reported revenue of $5.8 million (down 46.1% from FY2024) and a net loss of $116.8 million. Diluted EPS was -$16.95. The figures come from the XBRL data in the 10-K.
What did ACET report in its latest 8-K?
Adicet Bio Inc (ACET) filed an 8-K on November 13, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Director Andrew Sinclair resigned November 13, 2026 from the Board, Audit Committee and NCG Committee.
What are the latest ACET SEC filings?
Adicet Bio Inc (ACET) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on August 7, 2026.
What is ACET's SEC CIK number?
Adicet Bio Inc (ACET)'s SEC Central Index Key (CIK) is 1720580. EDGAR lists every ACET filing under that number.
Ask anything about ACET
The research agent reads ACET's filings, financials, insider trades and 13F holders, then answers with sources.